CALCIUM CATION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Ca
Molecular Weight	40.078
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++]

InChI

InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYSA-N

InChI=1S/Ca/q+2

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Hypocalcemia 73 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 511	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 175 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 438	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 438	Unknown Approved Use Unknown
Unknown 2596
Hypocalcemia 73 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8583	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Studies on the calcemic effect of intravenous secretin in humans.	1975 Jun	1220513
Ni2+ transport by the human Na+/Ca2+ exchanger expressed in Sf9 cells.	1999 May	10329968
Aluminum is a weak agonist for the calcium-sensing receptor.	1999 May	10231437
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.	1999 Nov	10535458
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.	1999 Sep 20	10509933
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.	2000 Aug	10970766
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density.	2000 Aug	10913914
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.	2000 Dec	11093801
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.	2000 Jan 15	10623810
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.	2000 Jul 17	10899114
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.	2000 Jun	10963052
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.	2000 Nov	11089548
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.	2000 Nov	11071371
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.	2000 Nov 10	11073891
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.	2001 Aug 28	11513607
Complement activation in factor D-deficient mice.	2001 Dec 4	11724962
Molecular and functional characterization of a family of rat brain T-type calcium channels.	2001 Feb 9	11073957
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.	2001 Jun	11425647
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.	2001 Mar 15	11238657
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.	2001 Nov	11701772
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.	2001 Nov	11606688
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.	2001 Nov 1	11705452
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.	2001 Oct 26	11679415
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.	2001 Sep	11500311
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.	2002 Feb	11872090
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.	2002 Sep	12181424
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.	2002 Sep 6	12065575
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.	2015 Aug 12	26265479
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.	2015 Sep 16	26376110
Lactose behaviour in the presence of lactic acid and calcium.	2016 Aug	27600977

Patents

Sample Use Guides

In Vivo Use Guide

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:09 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:09 GMT 2025`
Record UNII	2M83C4R6ZB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM CATION

Common Name

English

CA2+

Preferred Name

English

CALCIUM(2+)

Systematic Name

English

CALCIUM (II) ION

Common Name

English

CALCIUM(2+) ION

Common Name

English

CALCIUM ION(2+)

Common Name

English

CALCIUM, ION(CA2+)

Common Name

English

CALCIUM ION

Common Name

English

Classification Tree Code System Code

LOINC

13959-2